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Phronic Recurrent Myocardial Ischemic
njury Is Significantly Attenuated by Pre-Emptive
deno-Associated Virus Heme Oxygenase-1 GeneDelivery
lok S. Pachori, PHD,* Luis G. Melo, PHD,‡ Lunan Zhang, MD,* Scott D. Solomon, MD,†
ictor J. Dzau, MD*
urham, North Carolina; Boston, Massachusetts; and Kingston, Ontario, Canada
OBJECTIVES We assessed the hypothesis that overexpression of the antioxidant enzyme heme oxygenase
(HO)-1 may protect against chronic recurrent ischemia/reperfusion injury.
BACKGROUND Multiple and recurring episodes of myocardial ischemia can result in significant myocardial
damage, including myocyte death, fibrosis, and wall thinning, leading to impaired ventricular
function and cardiac failure.
METHODS In this study we used a closed-chest rodent model of chronic recurring myocardial ischemia
and reperfusion to investigate the efficacy of pre-emptive gene therapy in overexpressing the
antioxidant enzyme HO-1, using adeno-associated virus (AAV)-2 as the delivery vector.
RESULTS We show that constitutive overexpression of HO-1 can prevent myocardial wall thinning,
inflammation, fibrosis, and deterioration of cardiac function (as measured by echocardiography,
histology, and immunohistochemistry) induced by repeated transient myocardial ischemia and
reperfusion injury. With HO-1 therapy, there was a significant reduction in apoptosis as
determined by levels of markers of survival proteins and terminal deoxynucleotidyltransferase
dUTP nick end-labeling staining. This prevention of tissue damage was also associated with
reduction in superoxide generation.
CONCLUSIONS Taken together we provide the first evidence of the therapeutic efficacy of pre-emptive
AAV–HO-1 delivery for prevention against multiple ischemic injury. This approach protects
myocytes by simultaneously activating protective response and inhibiting pathological left
ventricular remodeling and, therefore, may be a useful cardio-protective strategy for patients
with coronary artery disease at a high risk for recurrent myocardial ischemia. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.038Cardiol 2006;47:635–43) © 2006 by the American College of Cardiology Foundation
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respite the significant advances in pharmacological and
nterventional therapies for acute coronary syndrome, isch-
mic heart disease remains the leading cause of death in the
estern world (1). Gene transfer strategy to overexpress a
herapeutic protein for gain of function has been proposed
s a strategy for the treatment of acute ischemic disease (2).
lthough several gene delivery studies have reported myo-
ardial salvage against acute ischemia and reperfusion (I/R)
3–5), they have the following limitations: the therapeutic
ene has to be delivered concomitant with acute I/R, the
uration of gene expression is often short, and there is no
vidence that gene therapy can be effective against multiple
schemic episodes over time. These problems are particularly
elevant clinically because the onset of acute ischemia is
npredictable, and in high-risk patients the ischemic events
re frequent, recurring, and potentially silent over a lifetime.
From the *Department of Medicine, Duke University Medical Center, Durham,
orth Carolina; †Department of Medicine, Brigham and Women’s Hospital,
arvard Medical School, Boston, Massachusetts; and the ‡Department of Physiol-
gy, Queen’s University, Kingston, Ontario, Canada. This work was supported in part
y grants from the National Institutes of Health to Dr. Dzau (HL 72010, HL 73219,
L58516, and HL 35610) and gifts from the Edna Mandel Foundation. Dr. Pachori
s supported by an NIH postdoctoral training grant (HL 69601-01). Dr. Melo is
anada Research Chair in Molecular Cardiology and a New Investigator of the Heart
nd Stroke Foundation of Canada, and is supported by grants from the Canadian
nstitute of Health Research.e
Manuscript received June 22, 2005; revised manuscript received August 23, 2005,
ccepted September 13, 2005.To address the first challenge, we have developed the
oncept of “pre-emptive gene therapy” by intramyocardial
dministration of the therapeutic gene (heme oxygenase
HO] and superoxide dismutase) in advance of the I/R
sing recombinant adeno-associated virus (AAV) delivery
6,7). Furthermore, we have shown that inducible gene
xpression using a hypoxia-responsive element to regulate
herapeutic gene expression is particularly effective in pro-
ecting the myocardium from acute I/R injury (8).
In this study we addressed the second challenge, i.e.,
hether our approach will provide long-term protection of
he myocardium against multiple, recurring episodes of
schemia over time. This issue represents a broad clinical
roblem in that tissue ischemia can be silent and can lead to
xtensive damage in many end organs (such as the heart,
rain, and kidney), resulting in progressive diseases such as
schemic cardiomyopathy and vascular dementia. We chose
O-1 as the therapeutic gene on the basis of evidence that
he catalytic by-products of this enzyme exert antioxidant
nd cytoprotective effects (9–12). However, it is not known
f pre-emptive delivery of the HO-1 gene can confer
yocardial protection in the context of chronic intermittent
pisodes of ischemia and reperfusion.
In this study we employed a rodent closed-chest model of
epetitive I/R induced over multiple days to examine the
ffect of intramyocardial rAAV–HO-1 gene therapy. Our
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Heme Oxygenase and Repeated I/R Injury February 7, 2006:635–43ata demonstrated that a single administration of AAV–
O-1 several weeks in advance of the injury protected
gainst deleterious effects of subsequent repeated episodes of
schemia and, importantly, resulted in the activation of
ellular survival processes that led to cytoprotective effects.
ETHODS
lasmids and HO-1 vector construction. A 986-bp frag-
ent of HO-1 containing the open reading frame sequence
as cleaved from the pBS KS cloning vector at KpnI-PstI
ites and subcloned at the corresponding sites in puc 18
lasmid. The insert was cut at EcoRI sites and cloned into
orresponding sites in rAAV2 backbone (pAAV–CMV–
O-1) containing the cytomegalovirus promoter and the
ovine growth hormone poly-adenylation signal flanked by
he AAV inverted terminal repeat sequences. Packaging,
ropagation, and purification of AAV-2 viral particles were
arried out at the Harvard Gene Therapy Initiative Core
acility (Boston, Massachusetts) by standard procedures.
NA extraction and reverse transcriptase-polymerase
hain reaction of HO-1. For reverse transcriptase-
olymerase chain reaction (RT-PCR) detection of HO-1
ranscripts, 100 ng of total RNA was used for first-strand
DNA synthesis and PCR amplification with the One-Step
latinum Taq RT-PCR kit (Life Technologies, Carlsbad,
alifornia). A 185-bp fragment was amplified for 30 cycles
ith the following hHO-1–specific primers: Forward,
_GCTCTTTGAGGAGTTGCAGG-3_; Reverse,
_-GTGTAAGGACCCATCGGAGA-3_.
n vivo gene delivery and I/R injury protocol. Male
prague-Dawley (SD) rats weighing 100 to 150 g were
urchased from Charles Rivers Laboratories (Indianapolis,
ndiana) and were maintained on a 12:12 h light:dark cycle
t an ambient temperature of 24°C and 60% humidity. Food
nd water were provided ad libitum. Myocardium gene
elivery of 2  1011 total particles of AAV–HO-1 and
AV–lacZ was performed on normal SD rats five weeks in
dvance of I/R injury as described previously (6). We
erformed the repeated I/R injury protocol as described
reviously (13). Briefly, an 8-0 Prolene suture (Ethicon,
Abbreviations and Acronyms
AAV  adeno-associated virus
ANOVA  analysis of variance
DHE  dihydroethidium
ECG  electrocardiogram
HO  heme oxygenase
I/R  ischemia and reperfusion
LAD  left anterior descending coronary artery
PBS  phosphate-buffered saline
RT-PCR  reverse transcriptase-polymerase chain
reaction
SD  Sprague-Dawley
TUNEL  terminal deoxynucleotidyltransferase dUTP
nick end-labelingomerville, New Jersey) was placed around the left anterior pescending artery; both ends of it were passed through a
iece of PE-90 tube (Becton Dickinson, Franklin Lakes,
ew Jersey), exteriorized through the thorax wall, and
laced beneath the skin. After seven days of recovery, the
kin was reopened, and the ends of the 8-0 suture were
ugged apart until ST-segment elevation occurred in elec-
rocardiogram. The 15-min I/R (resolution of the ST-
egment elevation) was performed daily for five days in both
acZ– and HO-1–treated rats. All surgical and experimental
rocedures were approved by the Harvard Medical Area
tanding Committee on Animals.
chocardiography. Animals underwent echocardiography
2 days after the last I/R injury. Rats were anesthetized with
sofluorane for echocardiographic examinations. Rat heart
ates ranged from 350 to 400 beats/min during echocardi-
graphy. Echocardiography was performed using a 6- to
5-MHz Ultraband Intraoperative Linear Array probe and
Sonos 5500 ultrasound imaging system (Philips Ultra-
ound, Andover, Massachusetts). Images were obtained
rom both the parasternal short and long axes, saved to
ine-loop utilizing native frame rates of 60 Hz, and
nalyzed utilizing an off-line analysis program. Endocardial
orders were traced and end-systolic and end-diastolic areas
nd volumes were calculated. Echocardiographic acquisition
nd analyses were performed by a technician who was
linded to treatment groups.
istology. Following the echocardiography, the hearts
ere harvested, washed in phosphate-buffered saline (PBS),
nd fixed in 10% formalin overnight at 4°C. Paraffin-
mbedded tissues were cut into 5-m-thin sections and
tained with hematoxylin and eosin and by Masson’s
richrome stain for collagen determination. Parallel sec-
ions were stained with mouse alpha-smooth muscle actin
ntibody (IMMH-2, Sigma, St. Louis, Missouri) for detec-
ion of myofibroblasts.
etection of superoxide ion generation. Superoxide gen-
ration was assessed via the conversion of dihydroethidium
DHE) to ethidium as previously described (14). Dihydro-
thidium enters the cell and is oxidized primarily by
uperoxide to yield fluorescent ethidium, which intercalates
nto deoxyribonucleic acid and is thereby retained in the cell.
riefly, hearts were harvested and snap-frozen in embed-
ing medium and stored at 80°C. Tissues were then
ectioned in 6-micron-thin stepwise sections from the apical
o the basal region of the heart. Sections were then washed
nce with 1X PBS and incubated with 5 M DHE in 1X
BS for 30 min at 37°C. Sections were then cover-slipped
ith the aqueous media and visualized with a laser scanning
onfocal microscope equipped with a krypton/argon laser.
xperimental and control tissues were processed and im-
ged in parallel by a person blind to the experiment. Laser
ettings were identical for acquisition of images from all the
pecimens. Fluorescence was detected with a 585-nm long-
ass filter.
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February 7, 2006:635–43 Heme Oxygenase and Repeated I/R Injurypoptosis detection by terminal deoxynucleotidyltrans-
erase dUTP nick end TUNEL staining. For this exper-
ment, tissues were harvested 12 hours after the last isch-
mic episode. Apoptosis was detected using a CardioTacs
taining kit (Trevigen, Gaithersburg, Maryland) as recom-
ended by the manufacturer. Briefly, unfixed frozen heart
ections were cut into 6-m-thin sections, thawed, dried,
ehydrated, and fixed with 3% paraformaldehyde for 10
in. Sections were then permeabilized with cytonin, and
ndogenous peroxide was quenched with a 5% hydrogen
eroxide solution. During apoptosis the chromosomal DNA is
igure 1. Schematic representation of repetitive ischemia and reperfusion
ene transfer. (A) Illustration of the experimental protocol for repetitive
ollowed by left anterior descending coronary artery (LAD) occlusion for 15
pisode, animals were subjected to echocardiography followed by tissue ha
lled circles). (C) Representative electrocardiogram (ECG) at basal show
igation. (D) Semi-quantitative reverse transcriptase-polymerase chain reac
ene transfer. (E) Western blot analysis of distribution of HO-1 proteinleaved by endonucleases to generate DNA fragments with bree 3=-hydroxyl residues. These 3= ends of cleaved DNA
ragments were labeled with the enzyme terminal deoxynu-
leotidyl transferase, which adds nucleotides at the site of
NA breaks. The incorporated biotinylated nucleotides
ere visualized by binding of streptavidin-horseradish per-
xidase followed by reaction with TACS Blue Label to
enerate a dark blue precipitate. The tissues were viewed
nder a standard light microscope where the apoptotic cells
re clearly and unequivocally distinguished by the dark blue
uclear staining. The positive control was generated by the
ddition of TACS-Nuclease, which generates the DNA
protocol and adeno-associated virus (AAV)-2-mediated intramyocardial
mia. AAV-HO-1 was administered five weeks in advance of the injury,
nd release performed daily for five days. Twelve days after the last ischemic
nd analyses. (B) Schematic diagram of the sites of injection (indicated by
normal tracing and showing an increase in ST-segment following LAD
(RT-PCR) detection of HO-1 transcript in left ventricle five weeks after
cted (ischemic) and non-injected (remote) areas of the left ventricle.(I/R)
ische
min a
rvest a
ing
tionreaks. Both TUNEL-positive and total nuclei were
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Heme Oxygenase and Repeated I/R Injury February 7, 2006:635–43ounted from 10 to 2 high magnification fields per sample,
nd the data were represented as the apoptotic index, which
as determined as the ratio of TUNEL-positive nuclei to
he total number of nuclei.
estern blots. Tissues were harvested 12 h after the last
pisode of I/R injury and homogenized in tris HCl buffer,
nd protein concentration was determined by Bradford assay.
rotein (12 g) was loaded on acrylamide gel, transferred to
olyvinylidiene difluoride membrane, and probed with either
cl-xl (Cell Signaling), bax (Cell Signaling, Danvers,
assachusetts), phospho-bad (Ser112) (Cell Signaling),
cl-2 (Novus Biologicals, Littleton, Colorado), and
O-1 (Stressgen, Canada) antibodies as described pre-
iously (8).
tatistics. All results are expressed as mean  SEM.
etermination of densitometric analyses of bax, bcl-xl, and
nhibitor of apoptosis protein gene expression were mea-
ured by one-way analysis of variance (ANOVA). For
chocardiography, ANOVA with a t-test post-hoc analysis
as performed to determine differences between the groups.
value of p  0.05 was considered to be statistically
ignificant.
igure 2. Effect of heme-oxygenase (HO)-1 gene transfer and repeated I/R
ays after the last ischemic episode demonstrates significant improvemen
able 1. Echocardiographic analyses after repeated I/R
Sham HO-1 LacZ
WT (mm) 0.117  0.002 0.115  0.003†‡ 0.088  0.003*
WT (mm) 0.117  0.002 0.115  0.003†‡ 0.088  0.003*
AVS (mm) 0.026  0.003 0.040  0.004†‡ 0.098  0.003*
AAS (mm) 0.143  0.013 0.183  0.006†‡ 0.313  0.003*
AVD (mm) 0.155  0.006 0.170  0.004†‡ 0.215  0.005*
AAD (mm) 0.417  0.006 0.445  0.005†‡ 0.518  0.005*
jection fraction (%) 81  3 72  2†‡ 51  2*
lacZ vs. sham, p  .05; †HO-1 vs. sham, not significant; ‡HO-1 vs. lacZ, p  0.05;
 5–6/group.
AWT  anterior wall thickness; I/R  ischemia and reperfusion; LAAD 
ong-axis area (diastole); LAAS  long-axis area (systole); LAVD  long-axis
olume (diastole); LAVS  long-axis volume (systole).ontrols. (* vs. sham; ** vs. lac Z. p  0.05, n  5 to 6/group). (B) Representativ
entricle cavity and decrease in wall thickness in lacZ-treated animals when comESULTS
AV-mediated intra-myocardial over-expression of
O-1 in rat hearts with repetitive I/R. We performed
he surgical studies according to the protocol described
reviously (13), with slight modification as described in
ethods. The rAAV-CMV-HO-1 vector was injected at
ve sites corresponding to the area at risk, as shown
reviously (6). We achieved almost 30% transduction effi-
iency using this protocol as demonstrated by HO-1 posi-
ive immunostaining (data not shown). Five weeks after
ene delivery, the chest was reopened and a suture was
laced around the left anterior descending coronary artery
LAD) (without ligation) and exteriorized underneath the
kin, and the chest was closed. After a one-week recovery
eriod, animals underwent the repetitive I/R protocol as
escribed in the Methods section (Fig. 1). Ischemia was
onfirmed by the increase in ST-segment as determined by
lectrocardiogram (ECG), and a representative tracing is
hown in Figure 1C. We determined HO-1 gene expression
y semi-quantitative RT-PCR and Western blot, respec-
ively, in the injected animals not subjected to I/R protocol.
s shown in Figure 1E, the HO-1 protein levels were
ignificantly higher in the HO-1-treated as compared to
acZ-treated animals. Moreover, the increase in HO-1
rotein was present in the ischemic area corresponding to
he area targeted by gene transfer, whereas in the extracts
rom the remote region of the left ventricle, the HO-1
rotein levels were not elevated and not significantly differ-
nt from the lacZ-treated ventricles.
ffect of HO-1 overexpression on ventricular function
nd remodeling of ischemic myocardium. We evaluated
he consequence of HO-1 gene transfer after repeated
schemia and reperfusion injury over time on ventricular
emodeling and function. Echocardiographic analyses per-
ormed one week after the last ischemic episode of repetitive
entricular function. (A) Echocardiographic analyses of rat myocardium 12
ejection fraction in HO-1-treated animals as compared to lacZ-treatedon v
t ine picture of M-Mode echocardiogram showing significant increase in left
pared to HO-1-treated group. Other abbreviations as in Figure 1.
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February 7, 2006:635–43 Heme Oxygenase and Repeated I/R Injuryigure 3. Effect of HO-1 gene transfer on ventricular remodeling and fibrosis after repeated I/R. (A) Masson Trichrome staining shows significant anterior
all thinning and collagen deposition two weeks after the last ischemic episode in lacZ-treated animals in contrast to HO-1–treated rats with decreased
ollagen deposition. Quantification of the fibrotic area as a percentage of total left ventricular area shows significant attenuation of fibrosis in the
O-1–treated animals as compared to saline or lacZ-treated controls. (n  4/group, * vs. saline and lacZ, p  0.05) (B) Representative alpha-smooth
uscle actin antibody staining demonstrates positive staining both in vessel walls as well as in the myocardium in lacZ-treated animals indicating higher
henotypic conversion to cardiac fibroblasts as compared to HO-1–treated animals, which demonstrated positive staining only in the vessel walls.
bbreviations as in Figure 1.
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Heme Oxygenase and Repeated I/R Injury February 7, 2006:635–43/R protocol demonstrated severe wall thinning and reduced
jection fraction in the lacZ-treated animals relative to the
O-1–treated animals (Table 1, Fig. 2). Left ventricular
unction and chamber dimensions in the HO-1–treated
nimals were almost identical to sham animals (Table 1),
ndicating nearly complete prevention of left ventricular wall
emodeling. Marked wall thinning and fibrosis were ob-
erved at one week after the last ischemic episode in the
acZ-treated controls, which was completely prevented in
O-1–treated animals (24.7  5.1 mm2 vs. 10.8  4.3
m2) (Fig. 3A).
Gross and microscopic histological analyses of hearts one
eek after the last ischemic episode in the lacZ-treated
nimals revealed severe wall thinning, inflammatory cell
nfiltration, and collagen deposition that was absent in the
igure 4. Expression of markers of apoptosis after repeated I/R. (A) Repre
yocardial samples obtained 12 h after the last episode of intermittent I
hospho-bad was elevated in the HO-1–treated animals. There was no ch
ithout I/R injury was used as a negative control. Abbreviations as in FigO-1–treated hearts. In addition, interstitial myofibro- slasts (stained with alpha-smooth muscle actin antibody)
ere observed in the ischemic area in the lacZ-treated
nimals, while HO-1–treated animals exhibited only a
poradic presence of these cells (Fig. 3B). Quantitatively,
here was a significant decrease in the smooth muscle actin
ositive area in the HO-1–treated animals as compared to
acZ- or saline-treated controls (3,733  719 mm2 vs.
4,877  2,800 mm2 or 11,674  1,572 mm2).
O-1–mediated protection after repetitive I/R is asso-
iated with decreased apoptosis and reduction in super-
xide generation. To determine the mechanism of cardio-
rotection by HO-1 overexpression, we harvested the
issues 12 h after the last ischemic episode and measured the
evels of the markers of apoptosis by Western blots and
uantitated cellular apoptosis by TUNEL staining. As
tive Western blots of two samples from each group (except in sham) from
B) Bcl-2 and Bcl-xl were highly induced in lacZ-treated animals, while
in levels of bax and alpha-sacrcomeric actin levels. HO-1–injected animal
.senta
/R. (
angehown in Figure 4, 12 h after the last ischemic episode, there
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February 7, 2006:635–43 Heme Oxygenase and Repeated I/R Injuryas a significant increase in levels of anti-apoptotic proteins,
cl-2 and bcl-xl, in lacZ-treated animals. Furthermore,
here was a significant increase in phosphorylated bad at Ser
12, in HO-1–treated animals compared to lacZ-treated
ontrols (Fig. 4). There was no change in the expression of
ax and alpha-sarcomeric actin protein levels between the
ifferent groups. It is important to note that HO-1 overex-
ression alone (without myocardial I/R injury) did not
nduce changes in the levels of survival proteins. At the same
ime, apoptotic cell death in the myocardium, as measured
y TUNEL staining was reduced by approximately 50% in
he HO-1–treated animals when compared to lacZ-treated
nimals (0.31 0.045 vs. 0.59 0.035, p 0.005) (Fig. 5).
To determine if overexpression of heme-oxygenase can
revent reperfusion-mediated generation of reactive oxygen
pecies, we evaluated accumulation of superoxide ion
igure 5. Effect of HO-1 gene transfer on myocardial apoptosis after repe
erminal deoxynucleotidyltransferase dUTP nick end-labeling (TUNEL) st
ewer numbers of TUNEL-positive cells in HO-1–treated animals in con
to 6/group). Apoptotic index was determined as described in Methods.O2
· ) by DHE staining in situ. Conversion of DHE to pthidium by superoxide anion resulted in nuclear fluores-
ence. Tissues from HO-1–treated animals consistently
howed a decreased number of ethidium-positive nuclei
ompared to lacZ-treated animals, indicating the attenua-
ion in the generation of reactive oxygen species (Fig. 6).
ISCUSSION
ecause the occurrence of I/R is unpredictable and recur-
ing, we hypothesize that pre-emptive administration of a
herapeutic gene by a vector that enables long-term expres-
ion may provide effective long-term protection against
hronic multiple episodes of I/R and may be ideal for
igh-risk patients who experience recurring episodes of
schemia. In this study, our data show that prior delivery of
AV–HO-1 five weeks in advance provides significant
/R. Representative micrograph demonstrating apoptosis as determined by
g in heart sections after five days of repeated I/R. There were significantly
o lacZ-treated controls (0.31  0.045 vs. 0.59  0.035, p  0.005, n 
r abbreviations as in Figure 1.ated I
ainin
trast trotection against recurring multiple I/R injury and the
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Heme Oxygenase and Repeated I/R Injury February 7, 2006:635–43evelopment of myocardial damage as characterized by
iffuse focal fibrosis, wall thinning, and ventricular dilation
n the absence of evidence of a large infarct.
Several biological properties of AAV make it a suitable
ector for long-term cardioprotective gene therapy. Adeno-
ssociated virus is weakly immunogenic, thereby circumventing
robust immune response by the host (15,16). Studies from
ur laboratory and others have demonstrated that AAV can
rovide stable expression of the transgene with long-term
roduction of the therapeutic protein (17,18), thus making it
n attractive vehicle for use in chronic human gene therapy
19,20). This pre-emptive approach for myocardial protection
epresents a significant departure from the current therapeutic
trategies, which focus on rescue and/or reversal of acute injury
nd whose efficacy is limited by a narrow time window for
uccessful therapeutic intervention (21). In contrast, a preven-
ive gene-transfer strategy requiring only a single administra-
ion of the therapeutic gene obviates the constraint of time and
rovides sustained protection against the deleterious effects of
hronic recurring I/R injury.
Our results illustrate several important differences between
he single prolonged ischemic injury model reported previously
6) and the repetitive transient ischemic injury model, includ-
ng morphological and histological alterations, changes in
entricular dimensions, and changes in expression levels of
urvival proteins. The histopathology of the myocardium in
ur animal model shows diffuse focal fibrosis which is distinc-
ive from a large area of myocardial scarring resulting from
issue infarction caused by a single prolonged occlusion of the
oronary artery (with or without reperfusion). A key difference
n molecular response between the two models is in the
xpression pattern of survival proteins such as bcl-2. In the
ingle-injury model (6), the level of bcl-2 was reduced in the
acZ control infarcted myocardium, in contrast to the HO-1–
reated myocardium. Furthermore, there were no differences in
evels of bad and bcl-xl between the treated and the untreated
earts that had undergone a single I/R injury (6). In compar-
son, in the repeated ischemia model, the levels of bcl-2 and
cl-xl were significantly elevated in lacZ control hearts as
igure 6. In situ detection of reactive oxygen species in rat myocardium
icroscopic sections of myocardium labeled with the oxidative dye dihydro
s oxidized to EtBr by O2
. At identical laser settings, fluorescence in
ontrols and is similar to the sham controls.ompared to the HO-1–treated hearts, while the levels of ihosphorylated bad were higher in the HO-1–treated than in
he lacZ-treated hearts. These divergent results between the
wo models would suggest that, unlike the infarcted myocar-
ium, the myocardium undergoing repeated brief ischemic
pisodes is not completely irreversibly injured.
In the hearts of lacZ-treated animals, there was a signif-
cant upregulation of bcl-xl and bcl-2 proteins when com-
ared to HO-1–treated or sham animals. However, there
as no difference in the levels of bax protein among different
roups. Bcl-2 promotes cell survival by forming het-
rodimers with bax protein that otherwise induces apopto-
is. The enhanced expression of bcl-2 protein in the lacZ-
reated hearts in the absence of changes in the quantity of
ax protein strongly suggests that compensatory cell survival
echanisms are activated in the failing myocardium. Our
esults are also supported by studies from Olivetti et al. (22),
ho demonstrated similar upregulation of bcl-2 protein
ithout any changes in bax protein level in myocardial tissue
amples from end-stage heart failure patients. More impor-
antly, we demonstrated for the first time that overexpres-
ion of HO-1 led to increased levels of phosphorylated bad.
ur data are supported by several recent studies that have
emonstrated that phosphorylation of bad is good for cell
urvival (23). Recently, it has been demonstrated that
ddition of heme results in degradation of bad and upregu-
ation of bcl-xl expression in human neutrophils (24). Since
he main function of HO is to degrade heme and if heme
nactivates bad, then our data would suggest that overex-
ression of HO may not only prevent bad degradation but
lso induce its phosphorylation, which may be part of an
ndogenous survival gene program protecting against irre-
ersible cell loss. An important caveat of this study is that we
njected the transgene into normal myocardium. However,
n the clinical setting, it is likely that patients at high risk of
ecurrent ischemia may have scars or already hibernating
yocardium. It remains to be determined whether overex-
ression of HO in already scarred tissue affects an already
ltered expression pattern of survival proteins and histolog-
repeated I/R. Representative fluorescent photomicrographs of confocal
ium (DHE). Red fluorescence is generated when dihydroethidium DHE
O-1–treated animals is markedly decreased compared with lacZ-treatedafter
ethid
the Hcal changes.
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February 7, 2006:635–43 Heme Oxygenase and Repeated I/R InjuryThe hearts from HO-1 knock-out mice have greater
usceptibility to I/R injury (25), thus suggesting a protective
ole of HO-1 in myocardial injury. In addition, we have
reviously demonstrated that HO-1 markedly reduced
yocardial injury after a single episode of I/R injury (6,8).
he protective effect of HO-1 is, at least in part, due to the
nhibition of pro-inflammatory and pro-oxidant mecha-
isms activated by reperfusion (6,26), which can trigger the
ascade of events that leads to cell death. Thus, HO-1
verexpression may have a sparing effect on the ischemic
yocardium to reduce I/R-induced injury and prevent the
equence of events leading to cell loss and subsequent
entricular dysfunction. Indeed, HO-1 knock-out mice also
how significantly increased apoptosis after chronic expo-
ure to hypoxia (27), indicating a protective role of HO-1
gainst the development of apoptosis and fibrosis.
Reactive oxygen species play an important role in the
athophysiology of ischemic disease (28). Recently, Dewald et
l. (29) demonstrated that oxidative stress from the generation
f reactive oxygen species plays a role in the pathogenesis of
ilated cardiomyopathy in this chronic recurring ischemia
odel. Our data would suggest that overexpression of HO-1
ttenuated the development of systolic dysfunction by reducing
poptotic cell death via phosphorylation of survival proteins. In
ddition, HO-1 overexpression also prevented the accumula-
ion of reactive oxygen species. From this perspective, our
ndings may have further clinical implications as a protective
nd anti-remodeling strategy for high-risk patients with coro-
ary heart disease. A significant number of patients are not
uitable for surgical revascularization (21) and may be at risk of
umulative injury resulting from multiple episodes of I/R
njury. For these patients, a strategy that could simultaneously
onfer protection of the myocytes from repeated I/R insults,
otentiate the native protective responses in the myocardium,
nd activate mechanisms that inhibit pathological left ventric-
lar remodeling should prevent further damage and improve
urvival.
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